Hodgkin lymphoma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD20 2
• CD19 11
• PD-1 9
• CD30 9
• PD-L1 2
• BCL-2 2
• STAT3 0
• CD47 1
• JAK 1
• MYC 2
• TP53 0
• ALK 0
• BTK 1
• CD22 0
• IL-6 0
• AKT 0
• CTLA-4 0
• mTOR 0
• PI3K 0
• PRMT5 1
• ABL1 0
• BCMA 0
• CD123 1
• CD38 0
• EZH2 0
• METTL3 0
• NOTCH1 0
• NRF2 0
• TIM-3 0
• AMPK 0
• AXL 0
• BDNF 1
• CCR5 0
• CDK4/6 0
• CXCR4 0
• FGFR 0
• FLT3 0
• GLP-1 0
• HDAC 0
• IL-15 1
• IL-17 0
• MET 0
• MMP-9 0
• NLRP3 0
• PARP 0
• PRAME 0
• SGLT2 0
• SIRT1 0
• TERT 0
• TIGIT 0
• TLR4 0
• TNF 0

24 of 34+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R01

  Integrating AI and Deep Mutational Scanning to Predict the Cancer-Promoting Effect of Shelterin Mutations

  University of California Berkeley· Berkeley, United States· US$2,197,943 awarded in fiscal year 2026· until Aug 2029

• NIH NIAID · U01

  Leveraging JAK Inhibitors to Halt Autoimmune Attack Induced by Immune Checkpoint Inhibitors

  University of California Los Angeles· Los Angeles, United States· US$1,183,663 awarded in fiscal year 2026· until Jul 2031

• NIH NCI · R37

  Trajectories of Neurotoxicity Among Patients with Adolescent and Young Adult Hodgkin Lymphoma

  University of Rochester· Rochester, United States· US$814,967 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R50

  Bridging National and Local Trial Systems to Expand Adolescent/Young Adult Participation in NCTN and NCORP Networks

  Columbia University Health Sciences· New York, United States· US$187,037 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R50

  Radiation Oncology Integration and innovation: Enhancing Lymphoma Trial Design and Establishing a Particle Therapy Research Pathway

  Mayo Clinic Jacksonville· Jacksonville, United States· US$163,320 awarded in fiscal year 2026· until Aug 2031

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  SMART-SMAPs: a new paradigm of cell-free cytotoxic immunotherapy for resistant CLL

  Universita Degli Studi di Siena· Siena, Italy· EU contribution €150,000· until Mar 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the Interplay of Natural Killer Cells and Microbiome in Non-Hodgkin's Lymphoma (LINK-M)

  Luxembourg Institute of Health· Strassen, Luxembourg· EU contribution €216,240· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Integrated Assessment of Indoor Radon and Hazardous Air Pollutants in Non-Hodgkin Lymphoma – a Case-Control Study in a Radon-Prone Area (AlphaLymph)

  Universidad de Santiago de Compostela· Santiago De Compostela, Spain· EU contribution €242,593· until Feb 2029· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Studying the Microenvironment And Related Targets in Non-Hodgkin's Lymphoma (SMART-NHL)

  Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer· Barcelona, Spain· EU contribution €181,153· until Aug 2027

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Development and characterization of a novel CAR T-cell therapy for NHL (CARLY)

  Fundacio Institut de Recerca Contra la Leucemia Josep Carreras· Badalona, Spain· EU contribution €226,441· until Jun 2027

10 of 85 running projects, newest first. Listed amounts together: US$56.6m + €11.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

  NCT03598608· Merck Sharp & Dohme LLC· Updated 28 Jul 2026

  “Business Reason”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

  NCT02332668· Merck Sharp & Dohme LLC· Source

• Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

  NCT03407144· Merck Sharp & Dohme LLC· Source

• A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

  NCT04875195· Merck Sharp & Dohme LLC· Source

• A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

  NCT05508867· Merck Sharp & Dohme LLC· Source

• Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

  NCT03598608· Merck Sharp & Dohme LLC· Source

• Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)

  NCT02684292· Merck Sharp & Dohme LLC· Source

• A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)

  NCT06504394· Merck Sharp & Dohme LLC· Source

• Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

  NCT05008224· Merck Sharp & Dohme LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 5
• Mendelian Randomization Analysis 6
• CRISPR-Cas Systems 1
• Gene Expression Profiling 14
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 5
• Metabolomics 1
• Flow Cytometry 9
• Immunohistochemistry 19
• Liquid Biopsy 1
• Circulating Tumor DNA 6
• Xenograft Model Antitumor Assays 20
• Positron-Emission Tomography 21
• Magnetic Resonance Imaging 18
• Machine Learning 11
• Deep Learning 3
• Cohort Studies 30
• Genome-Wide Association Study 7

• CytoVI: deep generative modeling of antibody-based single cell data.

  Nat Methods, Sept 2026

• [Research Progress on the Application of Single-Cell Sequencing Technology in Diffuse Large B-Cell Lymphoma --Review].

  Zhongguo Shi Yan Xue Ye Xue Za Zhi, Aug 2026

• Single-cell sequencing uncovers clonal dynamics profiles and therapeutic resistance biomarkers in relapsed and refractory peripheral T-cell lymphoma.

  Front Immunol, Jul 2026

• Single-nucleus and spatial transcriptomics analyses reveal interplay between evolutionary dynamics and energy metabolism in primary cardiac lymphoma.

  Cancer Gene Ther, May 2026

• Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors.

  Nat Commun, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.